Regenxbio sees more enrollment in trials, shows $15M loss

In one case cited by the President’s Council of Advisors on Science and Technology in its report on the dangers of analyzing mixtures of DNA from several people, a prosecutor told the jury the chance of a mistaken match was one in 1.1 billion. A later analysis of the evidence put it at ‘closer to one in two.’ (Thinkstock)

(Thinkstock)

Regenxbio Inc., a Rockville biotechnology company focused on gene therapy, said it was continuing to advance its product candidates and increased its cash on hand as it showed a quarterly loss.

The company lost $14.5 million, or 47 cents per share, in its second quarter, which it ended with $208.5 million in cash, equivalents and securities, up from $159 million in at the end of 2016.

Regenxbio said it is seeing continued enrollment in its phase 1 clinical trial evaluating RGX-314 for the treatment of wet macular degeneration and in its Phase I/II clinical trial evaluating RGX-501 for the treatment of homozygous familial hypercholesterolemia, among other accomplishments.

The company expects its full-year 2017 cash burn to be between $75 million and $80 million.